<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283060</url>
  </required_header>
  <id_info>
    <org_study_id>H027</org_study_id>
    <nct_id>NCT02283060</nct_id>
  </id_info>
  <brief_title>Sleep and Cognition After Atripla to Stribild Switch</brief_title>
  <official_title>Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atripla and Stribild are two FDA-Approved one pill a day combination antiretroviral&#xD;
      medications given for the treatment of HIV. Both drugs are reasonably well tolerated.&#xD;
      However, efavirenz, a component of Atripla, is known to cause &quot;mental&quot; side effects.&#xD;
&#xD;
      This proposal aims to assess whether a switch from Atripla to Stribild for 12 weeks will be&#xD;
      associated with reversal of sleep and cognitive disturbances. Demonstrating changes upon&#xD;
      withdrawal of drug and substitution of a drug regimen not known to have an impact on sleep&#xD;
      and cognition may represent the best option to determine whether use of efavirenz is&#xD;
      associated with effects on sleep and cognition beyond the immediate period following&#xD;
      initiation of drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Stribild&#xD;
      (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat) are 2 FDA-approved 'one&#xD;
      pill once a day' combination antiretroviral medications given for the treatment of HIV. Both&#xD;
      have a common nucleoside reverse transcriptase inhibitor (NRTI) backbone of tenofovir (TDF)&#xD;
      and emtricitabine (FTC), but differ in the 3rd medication contained in the pill. Atripla&#xD;
      contains a non-nucleoside reverse transcriptase (NNRTI) drug efavirenz (EFV) while Stribild&#xD;
      (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat) contains an integrase&#xD;
      inhibitor elvitegravir with the drug cobicistat inactive against HIV but designed to simply&#xD;
      boost the level of elvitegravir.&#xD;
&#xD;
      Both drugs are reasonable well tolerated. However, efavirenz is known to cause 'mental'&#xD;
      side-effects. It is known that the initial use of EFV is associated with central nervous&#xD;
      system (CNS) toxicity. The symptoms of such toxicity include daytime sleepiness, or&#xD;
      alternatively inability to sleep, as well as vivid dreams including nightmares. The majority&#xD;
      of such symptoms are believed to resolve within weeks; however there is controversy as to&#xD;
      whether residual problems persist on a long term basis. Furthermore there are now reports of&#xD;
      long time cognitive dysfunction associated with the use of efavirenz. Whether this is related&#xD;
      to sleep disturbance is not clear. Studies to assess this impact have primarily involved&#xD;
      assessment of sleep and cognitive function in antiretroviral (ART)-naïve subjects as they are&#xD;
      initiated on first time ART that includes EFV. Such studies however are confounded by a&#xD;
      'return to health' phenomena as HIV per se is known to cause sleep and cognitive deficits .&#xD;
      There is controversy regarding whether use of efavirenz leads to long term disturbances in&#xD;
      sleep and cognition. HIV per se causes sleep and cognitive deficits6 and studies which have&#xD;
      tried to assess problems in antiretroviral-naïve subject's pre- and post- initiation of&#xD;
      efavirenz-based regimens may be confounded by a 'return to health' phenomena.&#xD;
&#xD;
      This proposal aims to assess whether a switch from efavirenz/emtricitabine/tenofovir&#xD;
      disoproxil fumarate to elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat&#xD;
      will be associated with reversal of sleep and cognitive disturbances. Demonstrating changes&#xD;
      upon withdrawal of drug and substitution of a drug regimen not known to have an impact on&#xD;
      sleep or cognition may represent the best option to determine whether use of EFV is&#xD;
      associated with effects on sleep and cognition beyond the immediate period following&#xD;
      initiation of drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sleep architecture assessed by formal sleep study</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in sleep architecture as assessed by formal sleep study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in neuropsychological performance global and subdomain neuropsychological test scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in global and subdomain neuropsychological test scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pittsburgh Sleep Quality Index Score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the frequency of use of sleep medications</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the quality of life index score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Stribild switch arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atripla control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stribild</intervention_name>
    <description>To be administered orally, once daily with food.</description>
    <arm_group_label>Stribild switch arm</arm_group_label>
    <other_name>Co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atripla</intervention_name>
    <description>To be administered orally, once daily at bedtime on an empty stomach</description>
    <arm_group_label>Atripla control arm</arm_group_label>
    <other_name>Co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  Age 18 to 65 years&#xD;
&#xD;
          -  On stable efavirenz/emtricitabine/tenofovir disoproxil fumarate regimen &gt; 12 months&#xD;
&#xD;
          -  Documented plasma HIV RNA &lt; 50 copies/ml within 3 months of entry&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any other antiretroviral drugs in addition to&#xD;
             efavirenz/emtricitabine/tenofovir disoproxil fumarate within 6 months of study entry&#xD;
&#xD;
          -  Any documented plasma HIV RNA &gt; 100 copies/ml within the past 6 months prior to study&#xD;
             entry&#xD;
&#xD;
          -  Chronic hepatitis B as assessed by positive hepatitis B surface antigen [HBsAg]&#xD;
&#xD;
          -  Chronic hepatitis C as assessed by positive hepatitis C antibody [HCVab], except with&#xD;
             proof of viral clearance and normal liver function tests&#xD;
&#xD;
          -  Other chronic disease which is uncontrolled or likely to interfere with study results&#xD;
&#xD;
          -  Acute illness within 2 weeks of entry&#xD;
&#xD;
          -  Previously documented history of OSA (obstructive sleep apnea)&#xD;
&#xD;
          -  Moderate to high risk of OSA defined as BMI (Body mass index) &gt; 30 plus two of the&#xD;
             following: habitual snoring, gasping/choking, observed apnea while sleeping, neck&#xD;
             circumference &gt; 17 inches&#xD;
&#xD;
          -  Severe depression based on the BDI-2 (Beck Depression Inventory - II)&#xD;
&#xD;
          -  Chronic daily receipt of medications associated with potential for sleep interference&#xD;
             (i.e. psychoactive drugs, steroids, decongestants, beta blockers)&#xD;
&#xD;
          -  Any immunomodulator, HIV vaccine, any other vaccine, or investigational therapy within&#xD;
             30 days of study entry.&#xD;
&#xD;
          -  Anticipated need for medications which are contraindicated as per Stribild package&#xD;
             insert&#xD;
&#xD;
          -  Any known contra-indication to use of Stribild (elvitegravir/emtricitabine/tenofovir&#xD;
             disoproxil fumarate/cobicistat)&#xD;
&#xD;
          -  Creatinine clearance (Cockcroft and Gault) &lt; 70 ml/min&#xD;
&#xD;
          -  The following lab values:&#xD;
&#xD;
               1. Hemoglobin &lt; 9.0&#xD;
&#xD;
               2. Absolute neutrophil count &lt; 500/μL&#xD;
&#xD;
               3. Platelet count &lt; 40,000/μL&#xD;
&#xD;
               4. AST (SGOT) and ALT (SGPT) &gt; 5x ULN&#xD;
&#xD;
          -  Active or recent past history (within past 5 years) of illicit substance or alcohol&#xD;
             use or abuse which, in the judgment of the Investigator, will interfere with the&#xD;
             patient's ability to comply with the protocol requirements&#xD;
&#xD;
          -  Pregnancy or breast-feeding, intent to become pregnant during the course of the study&#xD;
             or breast-feeding&#xD;
&#xD;
          -  Patients, who, in the opinion of the Investigator, are unable to comply with the&#xD;
             dosing schedule and protocol evaluation or for whom the study may not be advisable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorna Nagamine, RN</last_name>
    <phone>808-692-1333</phone>
    <email>lornan@hawaii.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hawaii Center for AIDS</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Nagamine</last_name>
      <phone>808-692-1333</phone>
      <email>lornan@hawaii.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Ogata-Arakaki</last_name>
      <phone>808-692-1332</phone>
      <email>ogataara@hawaii.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Shikuma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Soll, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominic Chow, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beau Nakamoto, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalpana Kallianpur, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tracie Umaki, Psy.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atripla</keyword>
  <keyword>Stribild</keyword>
  <keyword>HIV</keyword>
  <keyword>Sleep architecture</keyword>
  <keyword>Neuropsychological performance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Elvitegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

